Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherPULMONARY PHARMACOLOGY

Rupatadine, a New Potent, Orally Active Dual Antagonist of Histamine and Platelet-Activating Factor (PAF)

Manuel Merlos, Marta Giral, Dolors Balsa, Rosa Ferrando, Mireia Queralt, Anna Puigdemont, Julián Garcı́a-Rafanell and Javier Forn
Journal of Pharmacology and Experimental Therapeutics January 1997, 280 (1) 114-121;
Manuel Merlos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marta Giral
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dolors Balsa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Ferrando
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mireia Queralt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Puigdemont
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julián Garcı́a-Rafanell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Javier Forn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Rupatadine (UR-12592, 8-chloro-6,11-dihydro-11-[1-[(5-methyl3-pyridinyl)methyl]-4-piperidinylidene]-5H-benzo[5,6]cyclohepta[1,2b]pyridine) is a novel compound that inhibits both platelet-activating factor (PAF) and histamine (H1) effects through its interaction with specific receptors (K i app values against [3H]WEB-2086 binding to rabbit platelet membranes and [3H]-pyrilamine binding to guinea pig cerebellum membranes were 0.55 and 0.10 μM, respectively). Rupatadine competitively inhibited histamine-induced guinea pig ileum contraction (pA2 = 9.29 ± 0.06) without affecting contraction induced by ACh, serotonin or leukotriene D4(LTD4). It also competitively inhibited PAF-induced platelet aggregation in washed rabbit platelets (WRP) (pA2= 6.68 ± 0.08) and in human platelet-rich plasma (HPRP) (IC50 = 0.68 μM), while not affecting ADP- or arachidonic acid-induced platelet aggregation. Rupatadine blocked histamine- and PAF-induced effects in vivo, such as hypotension in rats (ID50 = 1.4 and 0.44 mg/kg i.v., respectively) and bronchoconstriction in guinea pigs (ID50 = 113 and 9.6 μg/kg i.v.). Moreover, it potently inhibited PAF-induced mortality in mice (ID50 = 0.31 and 3.0 mg/kg i.v. and p.o., respectively) and endotoxin-induced mortality in mice and rats (ID50 = 1.6 and 0.66 mg/kg i.v.). Rupatadine’s duration of action was long, as assessed by the histamine- and PAF-induced increase in vascular permeability test in dogs (42 and 34% inhibition at 26 h after 1 mg/kg p.o.). Rupatadine at a dose of 100 mg/kg p.o. neither modified spontaneous motor activity nor prolonged barbiturate-sleeping time in mice, which indicates a lack of sedative effects. Overall, rupatadine combines histamine and PAF antagonist activities in vivo with high potency, the antihistamine properties being similar to or higher than those of loratadine, whereas rupatadine’s PAF antagonist effects were near those of WEB-2086. Rupatadine is therefore a good candidate for further development in the treatment of allergic and inflammatory conditions in which both PAF and histamine are implicated.

Footnotes

  • Send reprint requests to: Dr. J. Forn, Research Center, J. Uriach & Cı́a, S.A., Degà Bahı́ 59, 08026 Barcelona, Spain.

  • Abbreviations:
    PAF
    platelet-activating factor
    PRP
    platelet-rich plasma
    HPRP
    human platelet-rich plasma
    WRP
    washed rabbit platelets
    BSA
    bovine serum albumin
    PBS
    phosphate buffered saline
    LTD4
    leukotriene D4
    • Received May 31, 1996.
    • Accepted September 13, 1996.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 280, Issue 1
1 Jan 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Rupatadine, a New Potent, Orally Active Dual Antagonist of Histamine and Platelet-Activating Factor (PAF)
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherPULMONARY PHARMACOLOGY

Rupatadine, a New Potent, Orally Active Dual Antagonist of Histamine and Platelet-Activating Factor (PAF)

Manuel Merlos, Marta Giral, Dolors Balsa, Rosa Ferrando, Mireia Queralt, Anna Puigdemont, Julián Garcı́a-Rafanell and Javier Forn
Journal of Pharmacology and Experimental Therapeutics January 1, 1997, 280 (1) 114-121;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherPULMONARY PHARMACOLOGY

Rupatadine, a New Potent, Orally Active Dual Antagonist of Histamine and Platelet-Activating Factor (PAF)

Manuel Merlos, Marta Giral, Dolors Balsa, Rosa Ferrando, Mireia Queralt, Anna Puigdemont, Julián Garcı́a-Rafanell and Javier Forn
Journal of Pharmacology and Experimental Therapeutics January 1, 1997, 280 (1) 114-121;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Effects of 8-Bromo-Cyclic GMP on Membrane Potential of Single Swine Tracheal Smooth Muscle Cells
  • Inhibition of 5-Lipoxygenase Diminishes Neurally Evoked Tachykinergic Contraction of Guinea Pig Isolated Airway
  • Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation
Show more PULMONARY PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics